Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

Paul Pharoah and colleagues evaluate the prognostic significance of immunohistochemical subtype classification in more than 10,000 breast cancer cases with early disease, and examine the influence of a patient's survival time on the prediction of future survival.

[1]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Zhiyuan Hu,et al.  Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Pharoah,et al.  Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? , 2009, British Journal of Cancer.

[4]  Päivi Heikkilä,et al.  NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer , 2008, Nature Genetics.

[5]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[6]  Carlos Caldas,et al.  Molecular Classification of Breast Carcinomas Using Tissue Microarrays , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[7]  Päivi Heikkilä,et al.  Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients , 2005, International journal of cancer.

[8]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[9]  John J Spinelli,et al.  Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. , 2005, Journal of the National Cancer Institute.

[10]  Carlos Caldas,et al.  PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer , 2010, Breast Cancer Research.

[11]  S. Bull,et al.  Prognostic Effect of Basal-Like Breast Cancers Is Time Dependent: Evidence from Tissue Microarray Studies on a Lymph Node–Negative Cohort , 2008, Clinical Cancer Research.

[12]  J. Peterse,et al.  Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[14]  N. Le,et al.  Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. , 1997, The New England journal of medicine.

[15]  Paul D.P. Pharoah,et al.  Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. , 2007, Journal of the National Cancer Institute.

[16]  Marc Tischkowitz,et al.  Use of immunohistochemical markers can refine prognosis in triple negative breast cancer , 2007, BMC Cancer.

[17]  T. Stephenson,et al.  A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. , 2002, Human molecular genetics.

[18]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Vierkant,et al.  A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches , 2007, Breast Cancer Research and Treatment.

[20]  Carlos Caldas,et al.  Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index , 2006, Clinical Cancer Research.

[21]  M. Fernö,et al.  Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers , 2007, Breast Cancer Research.

[22]  E. Paish,et al.  Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression , 2007, Histopathology.

[23]  R. Warren,et al.  Screening for breast cancer, time to think— and stop? , 1995, The Lancet.

[24]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[25]  S. Chanock,et al.  Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses , 2006, Human Genetics.

[26]  D. English,et al.  The Melbourne Collaborative Cohort Study. , 2002, IARC scientific publications.

[27]  K Holli,et al.  Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. , 2000, Journal of the National Cancer Institute.

[28]  Carlos Caldas,et al.  Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis , 2007, Nature Reviews Cancer.

[29]  Genica,et al.  Commonly studied single-nucleotide polymorphisms and breast cancer: Results from the Breast Cancer Association Consortium , 2006 .

[30]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Berry,et al.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. , 2006, JAMA.

[32]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[33]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[34]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[35]  B. Ponder,et al.  Association of a common variant of the CASP8 gene with reduced risk of breast cancer. , 2004, Journal of the National Cancer Institute.